Background: Anticoagulation is recommended as standard of care for venous
thromboembolism (VTE)(pulmonary embolism [PE]/deep vein thrombosis [DVT]), for which …

Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is available for use in the
treatment and secondary prevention of venous thromboembolism (VTE). Like other direct …

Background Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify
the treatment of venous thromboembolism. Methods In this randomized, double-blind study …

Background In the Apixaban for the Initial Management of Pulmonary Embolism and Deep‐
Vein Thrombosis as First‐Line Therapy (AMPLIFY) trial, apixaban was noninferior to …

Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-
dose regimen, may be an option for the extended treatment of venous thromboembolism …

Objective To compare the clinical efficacy and safety of apixaban with those of rivaroxaban
for the treatment of acute venous thromboembolism (VTE). Patients and Methods …

Introduction Data from clinical trials indicate that direct oral anticoagulants (DOACs) are
noninferior and safer than conventional therapy (low-molecular-weight heparin followed by …

In the AMPLIFY clinical trial, apixaban was non-inferior to warfarin plus subcutaneous
enoxaparin bridge therapy in the treatment of acute venous thromboembolism (VTE) and …

Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …

Purpose Compared with conventional therapy (enoxaparin followed by warfarin), the direct-
acting oral anticoagulant apixaban is thought to offer similar protection against recurrent …